Lobe Sciences appoints Nick Karakochuk to board of directors

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (FWB: LOBE.F) announced the appointment of Nick Karakochuk to its board of directors on January 13, 2026.

Karakochuk is a corporate and securities lawyer at DuMoulin Black LLP, where he focuses on mergers and acquisitions, public and private financing, corporate reorganizations, and governance matters. He advises public and private issuers on stock exchange requirements, securities regulatory compliance, and continuous disclosure obligations.

"Nick and I have worked together since I began serving as CEO of Lobe, and I am very confident that this is the right time to bring someone with his experience onto the Board," said Dr. Frederick D. Sancilio, chairman and chief executive officer of Lobe Sciences. "As we enter 2026, our focus is on disciplined execution and fostering continued momentum. Nick's expertise in governance, capital markets, and complex transactions will be highly valuable as we build on the progress made in fiscal 2025."

In connection with his appointment, Karakochuk received 3,500,000 restricted share units of the company under its equity incentive plan and applicable regulatory requirements.

Lobe Sciences is a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with unmet medical needs. The company pursues development through its subsidiaries, including a majority interest in Cynaptec Pharmaceuticals Inc. and wholly owned subsidiary Altemia Inc.

The information is based on a company press release statement.

You May Also Be Interested In

• Nscale targets up to $3B in US IPO as soon as September - Bloomberg
• Barclays sees music streaming growth narrow gap with Spotify
• Buyout firm Vista explores $3B sale of private markets data provider Allvue - Reuters